Do neural autoantibodies indicate neuroinflammation, and can arachidonic-acid biology amplify inflammatory pain signaling?

Neural autoantibodies and arachidonic-acid (AA) biology address different stages of a possible immune–inflammatory process: antibody results may identify immune recognition, while AA-derived mediators can modify signaling once tissue inflammation is active. Neither finding alone establishes a causal neurological or pain syndrome.

Neural autoantibodies and neuroinflammation

• Validated antigen-specific neural autoantibodies indicate immunoglobulin binding to the corresponding neural target. Interpretation is strongest with phenotype-concordant disease and orthogonal assay confirmation.
• Positivity alone does not diagnose pathogenic CNS inflammation or autoimmune encephalitis. Clinical significance requires a compatible subacute neurological syndrome, exclusion of alternatives, and objective support such as inflammatory CSF, MRI or EEG abnormalities, focal deficits, or unexplained seizures.
• Paired serum/CSF testing is informative because sensitivity is antibody-specific: CSF is particularly important for NMDAR and GFAP antibodies, whereas serum may be more sensitive for LGI1 or CASPR2. Low-titer, serum-only, or clinically unexpected findings can be misleading.

AA signaling, cytokines, and pain

• During inflammation or tissue injury, phospholipases release membrane AA, which COX pathways convert into prostanoids including PGE₂. EPA competition and a lower AA:EPA ratio can shift mediator production; in a human supplementation study this reduced baseline cutaneous PGE₂ and increased 12-HEPE after challenge.
• PGE₂ can signal through EP receptors on sensory neurons, activating cAMP–PKA and/or PLC–PKC pathways that modulate TRPV1 and voltage-gated sodium channels. This lowers nociceptor thresholds, increases firing, and can contribute to hyperalgesia and allodynia.
• Cytokine consequences are context-dependent: AA supplementation up to 1.5 g/day showed little or no effect on circulating TNF-α or IL-6, and PGE₂ may either promote or restrain cytokine responses depending on timing and cell type.

Bottom line

• Neural antibody positivity warrants rigorous clinical corroboration, not an assumption of neuroinflammation. If inflammation is demonstrably active, AA-predominant lipid biology provides a credible route to altered eicosanoid and pain signaling, but does not by itself prove elevated cytokines or cause of clinical pain.